Measles virus neutralizing antibodies in immunoglobulin lots produced from plasma collected in Europe or the United States
Measles virus neutralizing antibodies in immunoglobulin lots produced from plasma collected in Europe or the United States
复制标题
DOI：
10.1016/j.vaccine.2019.04.022
复制
发表时间：
2019-05-27
期刊：
影响因子：
5.5
通讯作者：
Kreil, Thomas R.
中科院分区：
文献类型：
--
作者：
Farcet, Maria R.;Karbiener, Michael;Kreil, Thomas R.
接种麻疹疫苗减少了疾病，尽管接种疫苗后麻疹病毒抗体（MVAb）水平低于自然感染。免疫球蛋白（IG）制剂因此含有降低的MVAb滴度。美国IG批次放行要求MVAb的最低滴度，但其他地区尚无同等信息。使用麻疹病毒中和试验，从US或EU血浆中分离的IG显示含有相似水平的MVAb，始终高于US法规要求，支持对MV感染的等效保护。因此，欧盟暴露后预防的剂量可以与美国FDA的治疗建议保持一致。(C)2019作者爱思唯尔有限公司出版
Vaccination against measles has reduced disease, although measles virus antibody (MVAb) levels are lower after vaccination than natural infection. lmmunoglobulin (IG) preparations thus contain decreasing MVAb titers. US IG lot release requires a minimum titer of MVAb, yet equivalent information is not available for other geographies. Using a measles virus neutralization assay, IG fractionated from US or EU plasma is shown to contain similar levels of MVAb always above US regulatory requirements, supportive of equivalent protection against MV infection. Thus, the dosage for post-exposure prophylaxis in the EU could be aligned with the US FDA's treatment recommendations. (C) 2019 The Authors. Published by Elsevier Ltd.